Navigation Links
Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development
Date:7/3/2008

IRVINE, Calif., July 3 /PRNewswire/ -- Antigen Discovery Inc. ("ADI", formerly ImmPORT Therapeutics Inc.), a leader in high throughput antigen/biomarker discovery using advanced genomics and proteomics tools, announced today that the Company was awarded a Phase II SBIR from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Center for Research Resources (NCRR). The $3 million grant will fund efforts to further develop ADI's protein microarray based serodiagnostic platform for applications in biodefense and emerging infectious diseases. ADI will collaborate with investigators at the Proteomics Core facility of the Pacific Southwest Regional Center of Excellence (PSW RCE), located at the University of California, Irvine.

"The major bottleneck that limits the translation of readily available genomic information into the development of next generation diagnostics, vaccines and therapeutics, is the continued lack of effective antigen and biomarker discovery tools," said Dr. Xiaowu Liang, CEO of ADI. "We are grateful that the SBIR program continues to fund ADI and our UCI collaborators in the further development of this exciting new technology platform that truly revolutionizes the screening and detection of disease markers."

"The focus of this grant is to commercialize some of the broad applications of the platform technology that were developed during previous funding phases. The establishment of a Good Manufactuing Practices (GMP) facility, and a Clinical Research Lab will enable us to offer diagnostic products and services to physicians, point of care facilities, developers of novel vaccines, and pharmaceutical researchers," added Dr. Huw Davies, the Principal Investigator on the SBIR grant. "By using our novel protein array systems and statistical algorithms, we can rapidly discover antigen sets that will provide serological tests that discriminate between different infections, or even between different stages of the same infection."

About Antigen Discovery Inc.

Antigen Discovery Inc. (formerly ImmPORT Therapeutics Inc.) is a privately held biotech company with innovative technologies that offer unprecedented advantages for the rapid development of safer and more effective vaccines and diagnostic products. The Company's high throughput proteome microarray chip fabrication and screening platform provides an order of magnitude of improvement over current antigen/biomarker discovery technologies. The technology also has potential applications in the identification of markers for autoimmune disease and cancer.


'/>"/>
SOURCE Antigen Discovery Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
2. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
3. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
4. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
5. Discovery by UC Riverside physicists could enable development of faster computers
6. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
7. Oncomine(TM) Again Key to Prostate Cancer Discovery
8. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
9. Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs
10. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
11. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 21, 2017 , ... Boston Strategic ... experience with Health Economics and Outcomes Research (HEOR) and ‘big data’ to provide ... US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. BSP ...
(Date:8/18/2017)... ... August 18, 2017 , ... OAI, a leading Silicon Valley, ... Industries, announces the new Model 800E front and backside, semi-automatic mask aligner system. ... aligners. OAI has already received and installed several orders for the ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... and Electrospraying line of nanofiber and nanoparticle fabrication instruments from ... lab to fully automated pilot plants and equipment for industrial manufacturing. All ...
(Date:8/16/2017)... ... August 16, 2017 , ... We are proud to announce ... at our Dilworth, MN site. The inspection took place Monday, July 31st through ... part of a routine Bioresearch Monitoring Program (BIMO) with the USFDA wherein multiple ...
Breaking Biology Technology:
(Date:4/17/2017)... 17, 2017 NXT-ID, Inc. (NASDAQ: NXTD ... filing of its 2016 Annual Report on Form 10-K on Thursday ... ... available in the Investor Relations section of the Company,s website at ... website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
Breaking Biology News(10 mins):